Treatment of feline leukemia virus-infected cats with paramunity inducer.
Two placebo-controlled double-blind trials were performed to determine the therapeutic efficacy of the paramunity inducer, Baypamun in feline leukemia virus (FeLV)-infected cats under controlled conditions. In the first study, 120 cats were involved; 60 cats were treated with Baypamun and 60 with a placebo preparation of virus-free cell culture medium. Dosage and administration of the drug over a 7-week period were performed according to the instructions given by the company. Remission of viremia occurred in 12% and 7% of the cats treated with Baypamun and placebo, respectively. This difference was not statistically significant. In the second study, 30 naturally infected cats were treated in a placebo-controlled double-blind trial. In total, 20 immunological, clinical, laboratory, and virological parameters were examined. No statistically significant differences could be demonstrated between Baypamun and placebo application. Therefore, FeLV infection was not influenced by Baypamun treatment.
Hartmann
K
K
I. Medizinische Tierklinik, Ludwig-Maximilians-Universität, Munich, Germany.
Block
A
A
Ferk
G
G
Vollmar
A
A
Goldberg
M
M
Lutz
H
H
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000818:Animals; D000956:Antigens, Viral / Q000032:analysis; D016516:CD4-CD8 Ratio; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology; D002415:Cats; D004311:Double-Blind Method; D004341:Drug Evaluation; D007109:Immunity; D005256:Leukemia Virus, Feline / Q000276:immunology*; D016582:Leukemia, Feline / Q000097:blood / Q000276:immunology / Q000628:therapy*; D019798:Neopterin / Q000097:blood; D016896:Treatment Outcome; D014765:Viral Vaccines / Q000627:therapeutic use*; D014766:Viremia / Q000276:immunology / Q000628:therapy / Q000662:veterinary
D000276:Adjuvants, Immunologic; D000956:Antigens, Viral; C076692:Baypamun HK; D014765:Viral Vaccines; D019798:Neopterin